Bridgeway Capital Management’s ALX Oncology ALXO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$153K Hold
76,072
﹤0.01% 1079
2025
Q4
$86K Buy
76,072
+40,072
+111% +$60.7K ﹤0.01% 1143
2025
Q3
$65.9K Buy
+36,000
New +$31.2K ﹤0.01% 1146
2025
Q1
Sell
-75,000
Closed -$125K 1178
2024
Q4
$125K Buy
+75,000
New +$115K ﹤0.01% 1084
2024
Q2
Sell
-20,000
Closed -$223K 1272
2024
Q1
$223K Sell
20,000
-13,500
-40% -$190K ﹤0.01% 1088
2023
Q4
$499K Sell
33,500
-15,000
-31% -$142K 0.01% 945
2023
Q3
$233K Hold
48,500
0.01% 1070
2023
Q2
$364K Buy
+48,500
New +$317K 0.01% 997

Other funds holding ALXO

Bridgeway Capital Management's ALXO Position: Q1 2026 in Review

Bridgeway Capital Management held its ALX Oncology (ALXO) position steady in Q1 2026 at 76,072 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #1079.

Bridgeway Capital Management first reported a position in ALXO in Q2 2023 and has held it in 8 quarters since. The position peaked at $499K in Q4 2023. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Bridgeway Capital Management held 76,072 shares of ALX Oncology worth $153K as of Q1 2026.
  • Bridgeway Capital Management left its ALX Oncology share count unchanged in Q1 2026.
  • ALX Oncology made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1079 holding.
  • Bridgeway Capital Management first reported a position in ALX Oncology in Q2 2023 and has held it in 8 quarters since.
  • Bridgeway Capital Management's ALX Oncology position peaked at $499K in Q4 2023.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.